13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001587114
Total reported value
$2.1B
$2.1B
36 檔
47.3%
According to the latest 13F quarterly dataset, EcoR1 Capital, LLC managed an equity portfolio of $2.1B at the end of Q2 2025, spanning 36 distinct U.S. exchange-listed positions.
In Q2 2025, EcoR1 Capital, LLC adopted a defensive or profit-taking posture, trimming 4 positions and completely liquidating 14 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ZYME | Zymeworks Inc | Stock-Other | 17.06% | +4.78% | +33.09% | |
| 2 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 12.19% | — | — | |
| 3 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 10.72% | -13.69% | EXIT | |
| 4 | ANAB | Anaptysbio Inc | Stock-Other | 10.36% | +7.31% | — | |
| 5 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 7.30% | -6.61% | EXIT | |
| 6 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 6.31% | — | — | |
| 7 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 4.00% | +0.88% | — | |
| 8 | QURE | uniQure N.V. | Stock-Other | 3.40% | — | — | |
| 9 | TNGX | Tango Therapeutics Inc | Stock-Other | 3.22% | — | — | |
| 10 | XNCR | Xencor Inc | Stock-Other | 2.86% | -1.12% | EXIT | |
| 11 | IMNM | Immunome Inc | Stock-Other | 2.25% | — | — | |
| 12 | JANX | Janux Therapeutics Inc | Stock-Other | 2.01% | — | — | |
| 13 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 1.72% | +0.31% | +568.97% | |
| 14 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 1.71% | +1.55% | +2.05% | |
| 15 | KURA | Kura Oncology Inc | Stock-Other | 1.43% | — | +59.07% | |
| 16 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.39% | — | — | |
| 17 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.34% | — | — | |
| 18 | NGNE | Neurogene Inc | Stock-Other | 1.13% | +0.85% | — | |
| 19 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.12% | — | — | |
| 20 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.10% | — | — | |
| 21 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.97% | -0.08% | -52.66% | |
| 22 | ALKS | Alkermes plc | Stock-Healthcare | 0.85% | — | — | |
| 23 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.84% | — | -10.33% | |
| 24 | MBX | Mbx Biosciences Inc | Stock-Other | 0.78% | +0.06% | -8.69% | |
| 25 | VYGR | Voyager Therapeutics Inc | Stock-Other | 0.72% | — | — | |
| 26 | PCRX | Pacira Biosciences Inc | Stock-Other | 0.65% | — | — | |
| 27 | REPL | Replimune Group Inc | Stock-Other | 0.47% | -0.32% | EXIT | |
| 28 | ✓ | Stock-Other | 0.46% | — | +443.06% | ||
| 29 | ADAPY | Adaptimmune Therapeutics-adr | Stock-Other | 0.39% | — | — | |
| 30 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.33% | — | — | |
| 31 | ✓ | Hillevax Inc | Stock-Other | 0.29% | — | — | |
| 32 | ATRA | Atara Biotherapeutics Inc | Stock-Other | 0.26% | +0.85% | — | |
| 33 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 0.12% | — | -47.58% | |
| 34 | MGNX | Macrogenics Inc | Stock-Other | 0.11% | — | — | |
| 35 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.11% | — | — | |
| 36 | SRZNW | Surrozen Inc-cw25 | Stock-Other | 0.04% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | 2662247D | Iteos Therapeutics Inc | +6.3% | NEW | New buy |
| 2 | ZYME | Zymeworks Inc | +4.9% | +33.09% | Add |
| 3 | TNGX | Tango Therapeutics Inc | +2.4% | — | Unchanged |
| 4 | ANAB | Anaptysbio Inc | +1.7% | — | Unchanged |
| 5 | LKFT | Lakefront Biotherapeutic-adr | +1.5% | +568.97% | Add |
| 6 | CRSP | CRISPR Therapeutics AG | +1.2% | — | Unchanged |
| 7 | VRNA | Verona Pharma PLC - Adr | +1.1% | NEW | New buy |
| 8 | ALKS | Alkermes plc | +0.9% | NEW | New buy |
| 9 | QURE | uniQure N.V. | +0.8% | — | Unchanged |
| 10 | PCRX | Pacira Biosciences Inc | +0.7% | NEW | New buy |
| 11 | IMNM | Immunome Inc | +0.6% | — | Unchanged |
| 12 | KURA | Kura Oncology Inc | +0.4% | +59.07% | Add |
| 13 | ✓ | +0.4% | +443.06% | Add | |
| 14 | AKRO | Akero Therapeutics Inc | +0.3% | — | Unchanged |
| 15 | ✓ | Hillevax Inc | +0.3% | NEW | New buy |
| 16 | NGNE | Neurogene Inc | +0.3% | — | Unchanged |
| 17 | MBX | Mbx Biosciences Inc | +0.2% | -8.69% | Trim |
| 18 | ETON | Eton Pharmaceuticals Inc | +0.2% | +2.05% | Add |
| 19 | TECX | Tectonic Therapeutic Inc | +0.1% | — | Unchanged |
| 20 | MGNX | Macrogenics Inc | +0.1% | NEW | New buy |
| 21 | ADAPY | Adaptimmune Therapeutics-adr | +0.1% | — | Unchanged |
| 22 | ATRA | Atara Biotherapeutics Inc | +0.1% | — | Unchanged |
| 23 | NUVB-WS | Nuvation Bio Inc -cw27 | 0% | — | Unchanged |
| 24 | SRZNW | Surrozen Inc-cw25 | 0% | — | Unchanged |
| 25 | REPL | Replimune Group Inc | 0% | — | Unchanged |
| 26 | UPB | Upstream Bio Inc | 0% | EXIT | Sold out |
| 27 | ALGS | Aligos Therapeutics Inc | 0% | EXIT | Sold out |
| 28 | TCRX | Tscan Therapeutics Inc | -0.1% | EXIT | Sold out |
| 29 | VYGR | Voyager Therapeutics Inc | -0.1% | — | Unchanged |
| 30 | PRME | Prime Medicine Inc | -0.1% | EXIT | Sold out |
| 31 | DAWNGBX | Day One Biopharmaceuticals I | -0.1% | — | Unchanged |
| 32 | RLAY | Relay Therapeutics Inc | -0.1% | EXIT | Sold out |
| 33 | WHWK | Whitehawk Therapeutics Inc | -0.1% | -47.58% | Trim |
| 34 | KLRS | Kalaris Therapeutics Inc | -0.1% | EXIT | Sold out |
| 35 | KROS | Keros Therapeutics Inc | -0.1% | EXIT | Sold out |
| 36 | MDGL | Madrigal Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 37 | RNAGBP | Avidity Biosciences Inc | -0.1% | -10.33% | Trim |
| 38 | SLDB | Solid Biosciences Inc | -0.2% | EXIT | Sold out |
| 39 | ORIC | Oric Pharmaceuticals Inc | -0.2% | -52.66% | Trim |
| 40 | JANX | Janux Therapeutics Inc | -0.3% | — | Unchanged |
| 41 | ✓ | Verve Therapeutics Inc | -0.3% | EXIT | Sold out |
| 42 | BCYC | Bicycle Therapeutics Plc-adr | -0.5% | EXIT | Sold out |
| 43 | DNA | Ginkgo Bioworks Holdings Inc | -0.5% | EXIT | Sold out |
| 44 | BEAM | Beam Therapeutics Inc | -0.6% | EXIT | Sold out |
| 45 | XNCR | Xencor Inc | -1% | — | Unchanged |
| 46 | CRNX | Crinetics Pharmaceuticals In | -1.2% | — | Unchanged |
| 47 | JAZZ | Jazz Pharmaceuticals plc | -1.9% | — | Unchanged |
| 48 | APLSUSD | Apellis Pharmaceuticals Inc | -3.2% | — | Unchanged |
| 49 | SRPT | Sarepta Therapeutics Inc | -4.9% | EXIT | Sold out |
| 50 | PRTA | Prothena Corporation plc | -8.5% | EXIT | Sold out |
According to official SEC Form 13F filings, EcoR1 Capital, LLC reported a total U.S. public equity portfolio value of $2.1B across 36 disclosed positions in Q2 2025.
During Q2 2025, EcoR1 Capital, LLC's top holdings by market value included ZYME (17.1%)、APLSUSD (12.2%)、JAZZ (10.7%). The largest single position, ZYME, represented 17.1% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ZYME, APLSUSD, JAZZ) accounted for 47.3% of total reported equity market value during Q2 2025.
Top New Position Initiated
2662247D
市值: $106.6M
Top Position Liquidated / Trimmed
PRTA
前期市值: $143.4M
In Q2 2025, EcoR1 Capital, LLC made 29 total portfolio adjustments, initiating 6 new buys, adding to 5 positions, trimming 4 holdings, and fully liquidating 14 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.